# Catequentinib in Patients Who Have Completed an Advenchen Study (A Compassionate Use Trial)

> **NCT05612191** · — · AVAILABLE · sponsor: **Advenchen Laboratories, LLC**

## Conditions studied

- Sarcoma,Soft Tissue
- Gynecologic Cancer

## Interventions

- **DRUG:** AL3818

## Key facts

- **NCT ID:** NCT05612191
- **Lead sponsor:** Advenchen Laboratories, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2022-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05612191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05612191, "Catequentinib in Patients Who Have Completed an Advenchen Study (A Compassionate Use Trial)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05612191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*